Clinical Trial Search

Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Time to Relapse During the Double-Blind Phase — 395.0; NA Days

Primary: Part-2 (Disease Progression): Time to First Treatment Failure — NA; NA days

Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Time to Relapse During the Double-Blind (DB) Phase — NA; NA Days

Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 98.1; 97.7; 97.4; 97.2 units on a scale — p=0.2053

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale

Primary: Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -14.6; -17.2; -10.0 Score on a Scale — p=0.440

Primary: Time to First Treatment Failure — 416; 226 Days

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59

Primary: Percentage of Participants Without Relapse at Week 48 During the Double-Blind Phase — 91.5; 90.0 Percentage of Participants

Primary: Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score — -8.9; -4.2 units on a scale — p=<0.05

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Time to Relapse of Psychotic Symptoms During 6 Weeks — 23.8; 16.9; 17.3 days

Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score — -26.7; -28.6; -21.2 points — p=0.05

Primary: Treatment Response — 41.64; 42.38; 22.5868; 27.2235 units on a scale — p=0.0493

Primary: Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 — 7.12; 7.76; 21.80 Percentage of patients — p=0.7871

Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants

Primary: Conversion to Psychosis — 1; 2 participants

Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05

Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170

Primary: Cognition Measured by AX-Continuous Performance Test (AX-CPT) D-prime Score — 2.7; 2.5; 2.3; 3.2 d prime score — p=<0.016